Philips (NYSE: PHG) announced today that it launched Transcend Plus, the next generation of its cardiovascular ultrasound offerings.
Amsterdam-based Philips said Transcend Plus, the latest version of its Epiq CVx and Affiniti CVx systems, delivers major advancements in image quality and AI. That includes newly FDA-cleared 2D and 3D image quality enhancements and a growing suite of AI-enabled clinical applications.
Philips says it designed the offering to help cardiology teams work smarter, not harder. It aims to deliver fast, reproducible results with uncompromising image quality and decision-making support.
Transcend Plus visibly improves sharpness, contrast and detail in its imaging, the company said. The upgrades support superior visualization of cardiac anatomy and function to enable more diagnostic confidence in challenging, complex cases. This update also includes a new 2D Auto EF Advanced feature, expanding AI capabilities in assessing cardiac function.
Philips said its new AI-powered offering supports left ventricular function assessment as automated tools minimize operator variability. It empowers fast, confident decisions across every cardiac care setting, including the echo lab, interventional suite or during outpatient assessments.
The company outlined three benefits of Transcend Plus: enhanced image quality, advanced AI integration and faster, more actionable insights.
“Transcend Plus represents a bold leap forward in the evolution of echocardiography, reinforcing our commitment to continuous innovation, empowering clinicians with AI-driven tools that enhance confidence, accelerate decision-making, and elevate care at every stage of the cardiac journey,” said David Handler, business leader, Cardiology Ultrasound at Philips. “Transcend Plus is more than an advancement – it’s a clear statement of Philips’ leadership in cardiovascular ultrasound. Building on the momentum of our original Transcend launch, Transcend Plus brings the full power of AI integration to the forefront, giving clinicians the confidence, speed, and precision they need to lead in cardiac care – today and into the future.”
